The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $654,345.00 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The award, effective December 1, 2024 through November 30, 2029, will support research to explore the effects of blocking activin type II receptor (ACTRII) signaling on systemic energy balance and metabolism, both during and after the cessation of GLP-1/GIP receptor agonist treatment. The research aims to elucidate the tissue-specific mechanisms by which ACTRII blockade alters muscle and adipose tissue physiology, with the goal of developing therapeutic approaches to maximize fat loss while preserving lean muscle mass for improved and sustained weight loss outcomes in obesity treatment.
Generated 3/4/25, 4:47 AM